Client programs using CHOMax follow platform-defined workflows and phase-appropriate practices across the development lifecycle.

Traditional approaches to biologics production—relying on one-size-fits-all expression vectors and empirical process optimization—have led to inefficiencies in expression, scalability, and ...

New offering provides drug developers with flexible and powerful cell line development options for monoclonal antibodies, multi-specific and complex molecules SEATTLE--(BUSINESS WIRE)-- As drug ...

TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. The platform has achieved ...